Adjuvant Icotinib Treatment Duration and Survival Benefits in Patients With Stage II–IIIA EGFR+ Lung Adenocarcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
ESMO Open
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Randomized phase II adjuvant trial to compare two treatment durations of icotinib (2 years versus 1 year) for stage II-IIIA EGFR-positive lung adenocarcinoma patients (ICOMPARE study)
ESMO Open 2023 Jun 20;8(4)101565, C Lv, R Wang, S Li, S Yan, Y Wang, J Chen, L Wang, Y Liu, Z Guo, J Wang, Y Pei, L Yu, N Wu, F Lu, F Gao, J Chen, Y Liu, X Wang, S Li, B Han, L Zhang, Y Ma, L Ding, Y Wang, X Yuan, Y YangFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.